Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

BridgeBio Pharma Acquires Remaining Shares of Eidos Therapeutics

October 5, 2020

Biotechnology

BridgeBio Pharma agreed to acquire all outstanding shares of Eidos Therapeutics that it does not already own, offering Eidos shareholders the choice of 1.85 BridgeBio shares or cash (up to a $175 million aggregate cash cap). The transaction reunites Eidos and its lead candidate acoramidis with BridgeBio’s clinical development and commercial infrastructure to accelerate development and potential global launch of the therapy for ATTR.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Scipher Medicine Acquires CrossBridge to Add Real-time Patient Data and Analytics Platform

January 10, 2023

Data & Analytics

Scipher Medicine has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data management and analytics capabilities. The acquisition (closed; terms not disclosed) adds CrossBridge's SaaS value-based care platform to enable real-time mapping of patient molecular, clinical and claims data and to support Scipher's precision immunology offerings such as the PrismRA test.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.